Glenmark Pharma is currently trading at Rs. 323.70, up by 3.70 points or 1.16% from its previous closing of Rs. 320.00 on the BSE.
The scrip opened at Rs. 320.50 and has touched a high and low of Rs. 325.35 and Rs. 319.50 respectively. So far 36186 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 389.75 on 07-Dec-2010 and a 52 week low of Rs. 241.60 on 28-Feb-2011.
Last one week high and low of the scrip stood at Rs. 329.80 and Rs. 313.00 respectively. The current market cap of the company is Rs. 8652.12 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 38.09% and 13.60% respectively.
Glenmark Pharmaceuticals subsidiary - Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (USFDA) for Zolmitriptan, generic version of IPR’s migraine treatment Zomig tablets.
The tentative approval granted by the US FDA is for 2.5mg and 5mg tablets of Zolmitriptan and constitutes one of two tentative approvals granted for a generic version of the drug.
Glenmark’s current portfolio consists of 73 products authorized for distribution in the US marketplace and over 40 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
Glenmark Generics is a subsidiary of Glenmark Pharmaceuticals and aims to be a global integrated Generic and API leader. It has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1854.15 |
Dr. Reddys Lab | 1350.75 |
Cipla | 1497.80 |
Lupin | 2357.65 |
Zydus Lifesciences | 1001.20 |
View more.. |